Mark Thomas1,2, Chris Hopkins2, Eamon Duffy2, Daniel Lee3, Pierre Loulergue4, Diego Ripamonti5, David A Ostrov6, Elizabeth Phillips7,8,9. 1. Department of Molecular Medicine and Pathology, Faculty of Medical and Health Sciences, University of Auckland, New Zealand. 2. Infectious Diseases Department, Auckland City Hospital, New Zealand. 3. Department of Internal Medicine, University of California San Diego, California, USA. 4. Centre d'Investigation Clinique Cochin-Pasteur de Vaccinologie Cochin-Pasteur, Hôpital Cochin, Paris, France. 5. Department of Infectious Diseases, Ospedale Papa Giovanni XXIII, Bergamo, Italy. 6. Department of Pathology, Immunology and Laboratory Medicine, University of Florida College of Medicine, Gainesville, FL, USA. 7. Department of Pharmacology, Oates Institute for Experimental Therapeutics, Vanderbilt University Medical School, Nashville, Tennessee, USA. 8. Department of Medicine, Vanderbilt University, Nashville, Tennessee, USA. 9. Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, Western Australia.
Abstract
Background: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare, severe adverse event during treatment with raltegravir. The occurrence of DRESS syndrome during treatment with other drugs is strongly associated with particular HLA alleles. Methods: We performed HLA testing in 3 of the 5 patients previously reported to have developed raltegravir-induced DRESS syndrome and in 1 previously unreported patient. We then used virtual modeling to visualize interactions between raltegravir and the imputed HLA molecule. Results: Five of the 6 patients who developed raltegravir-induced DRESS syndrome were African, and 1 was Hispanic. HLA typing was performed in 4 patients, all of whom carried both the HLA-B*53 allele and the HLA-C*04 allele to which it is commonly haplotypic. No other HLA alleles were shared by all of the tested patients. Given the approximate prevalence of HLA-B*53 carriage in African (20%) and Hispanic (6%) populations, the probability of all 4 patients being HLA-B*53 carriers, and 2 of 3 African patients being homozygous for HLA-B*53:01, is approximately 0.00002. Conclusions: These data implicate the prevalent African allele HLA-B*53:01 in the immunopathogenesis of raltegravir-induced DRESS syndrome. Although the immunopathogenic mechanisms are currently unknown, virtual modeling suggests that raltegravir may bind within the antigen binding cleft of the HLA-B*53:01 molecule, but not within the closely related HLA-B*35:01 molecule. Further studies are necessary to confirm the strength of the association between carriage of the HLA-B*53:01 allele and raltegravir-induced DRESS syndrome, and the potential utility of HLA screening before raltegravir treatment.
Background: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a rare, severe adverse event during treatment with raltegravir. The occurrence of DRESS syndrome during treatment with other drugs is strongly associated with particular HLA alleles. Methods: We performed HLA testing in 3 of the 5 patients previously reported to have developed raltegravir-induced DRESS syndrome and in 1 previously unreported patient. We then used virtual modeling to visualize interactions between raltegravir and the imputed HLA molecule. Results: Five of the 6 patients who developed raltegravir-induced DRESS syndrome were African, and 1 was Hispanic. HLA typing was performed in 4 patients, all of whom carried both the HLA-B*53 allele and the HLA-C*04 allele to which it is commonly haplotypic. No other HLA alleles were shared by all of the tested patients. Given the approximate prevalence of HLA-B*53 carriage in African (20%) and Hispanic (6%) populations, the probability of all 4 patients being HLA-B*53 carriers, and 2 of 3 African patients being homozygous for HLA-B*53:01, is approximately 0.00002. Conclusions: These data implicate the prevalent African allele HLA-B*53:01 in the immunopathogenesis of raltegravir-induced DRESS syndrome. Although the immunopathogenic mechanisms are currently unknown, virtual modeling suggests that raltegravir may bind within the antigen binding cleft of the HLA-B*53:01 molecule, but not within the closely related HLA-B*35:01 molecule. Further studies are necessary to confirm the strength of the association between carriage of the HLA-B*53:01 allele and raltegravir-induced DRESS syndrome, and the potential utility of HLA screening before raltegravir treatment.
Authors: S H Kardaun; A Sidoroff; L Valeyrie-Allanore; S Halevy; B B Davidovici; M Mockenhaupt; J C Roujeau Journal: Br J Dermatol Date: 2007-03 Impact factor: 9.302
Authors: Rebecca Pavlos; Simon Mallal; David Ostrov; Soren Buus; Imir Metushi; Bjoern Peters; Elizabeth Phillips Journal: Annu Rev Med Date: 2014-10-27 Impact factor: 13.739
Authors: Martin Markowitz; Bach-Yen Nguyen; Eduardo Gotuzzo; Fernando Mendo; Winai Ratanasuwan; Colin Kovacs; Guillermo Prada; Javier O Morales-Ramirez; Clyde S Crumpacker; Robin D Isaacs; Lucinda R Gilde; Hong Wan; Michael D Miller; Larissa A Wenning; Hedy Teppler Journal: J Acquir Immune Defic Syndr Date: 2007-10-01 Impact factor: 3.731
Authors: M A Boyd; N Kumarasamy; C L Moore; C Nwizu; M H Losso; L Mohapi; A Martin; S Kerr; A H Sohn; H Teppler; O Van de Steen; J-M Molina; S Emery; D A Cooper Journal: Lancet Date: 2013-06-15 Impact factor: 79.321
Authors: Niamh M Keane; Rebecca K Pavlos; Elizabeth McKinnon; Andrew Lucas; Craig Rive; Christopher C Blyth; David Dunn; Michaela Lucas; Simon Mallal; Elizabeth Phillips Journal: AIDS Date: 2014-08-24 Impact factor: 4.177
Authors: Daniel F Carr; Mas Chaponda; Andrea L Jorgensen; Elena Cornejo Castro; Joep J van Oosterhout; Saye H Khoo; David G Lalloo; Robert S Heyderman; Ana Alfirevic; Munir Pirmohamed Journal: Clin Infect Dis Date: 2013-01-29 Impact factor: 9.079
Authors: Rebecca Pavlos; Katie D White; Celestine Wanjalla; Simon A Mallal; Elizabeth J Phillips Journal: Immunol Allergy Clin North Am Date: 2017-11 Impact factor: 3.479